|
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________ |
|
SCHEDULE 13G (Rule 13d-102)
|
|
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1
|
|
Barrier Therapeutics, Inc. |
|
(Name of Issuer)
|
|
Common Stock, $.0001 par value |
|
(Title of Class of Securities)
|
|
06850R 10 8 |
|
(CUSIP Number)
|
|
December 31, 2008 |
|
(Date of Event Which Requires Filing of this Statement) |
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
o Rule 13d-1(b)
o Rule 13d-1(c)
x Rule 13d-1(d)
_________________________
1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.
|
CUSIP No. 06850R 10 8 |
Page 2 of 7 Pages |
|
1. |
Name of Reporting Person I.R.S. Identification No. of Above Person (Entities Only) |
Johnson & Johnson 22-1024240 |
||
|
2. |
Check the Appropriate Box if a Member of a Group |
(a) o (b) o |
||
|
3. |
SEC Use Only |
|
||
|
4. |
Citizenship or Place of Organization |
New Jersey |
||
|
Number of Shares Beneficially Owned by Each Reporting Person With |
5. |
Sole Voting |
0 |
|
|
6. |
Shared Voting |
0 |
||
|
7. |
Sole Dispositive |
0 |
||
|
8. |
Shared Dispositive Power |
0 |
||
|
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person |
0 |
||
|
10. |
Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares |
o |
||
|
11. |
Percent of Class Represented by Amount in Row (9) |
0 |
||
|
12. |
Type of Reporting Person |
CO |
||
|
|
-2- |
|
CUSIP No. 06850R 10 8 |
Page 3 of 7 Pages |
|
1. |
Name of Reporting Person I.R.S. Identification No. of Above Person (Entities Only) |
Johnson & Johnson Consumer Companies, Inc. |
||
|
2. |
Check the Appropriate Box if a Member of a Group |
(a) o (b) o |
||
|
3. |
SEC Use Only |
|
||
|
4. |
Citizenship or Place of Organization |
New Jersey |
||
|
Number of Shares Beneficially Owned by Each Reporting Person With |
5. |
Sole Voting |
0 |
|
|
6. |
Shared Voting |
0 |
||
|
7. |
Sole Dispositive |
0 |
||
|
8. |
Shared Dispositive Power |
0 |
||
|
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person |
0 |
||
|
10. |
Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares |
o |
||
|
11. |
Percent of Class Represented by Amount in Row (9) |
0 |
||
|
12. |
Type of Reporting Person |
CO |
||
|
|
-3- |
|
CUSIP No. 06850R 10 8 |
Page 4 of 7 Pages |
|
1. |
Name of Reporting Person I.R.S. Identification No. of Above Person (Entities Only) |
Johnson & Johnson Development Corporation 22-2007137 |
||
|
2. |
Check the Appropriate Box if a Member of a Group |
(a) o (b) o |
||
|
3. |
SEC Use Only |
|
||
|
4. |
Citizenship or Place of Organization |
New Jersey |
||
|
Number of Shares Beneficially Owned by Each Reporting Person With |
5. |
Sole Voting |
0 |
|
|
6. |
Shared Voting |
0 |
||
|
7. |
Sole Dispositive |
0 |
||
|
8. |
Shared Dispositive Power |
0 |
||
|
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person |
0 |
||
|
10. |
Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares |
o |
||
|
11. |
Percent of Class Represented by Amount in Row (9) |
0 |
||
|
12. |
Type of Reporting Person |
CO |
||
|
|
-4- |
|
CUSIP No. 06850R 10 8 |
Page 5 of 7 Pages |
|
1. |
Name of Reporting Person I.R.S. Identification No. of Above Person (Entities Only) |
Ortho-McNeil-Janssen Pharmaceuticals, Inc. |
||
|
2. |
Check the Appropriate Box if a Member of a Group |
(a) o (b) o |
||
|
3. |
SEC Use Only |
|
||
|
4. |
Citizenship or Place of Organization |
Delaware |
||
|
Number of Shares Beneficially Owned by Each Reporting Person With |
5. |
Sole Voting |
0 |
|
|
6. |
Shared Voting |
0 |
||
|
7. |
Sole Dispositive |
0 |
||
|
8. |
Shared Dispositive Power |
0 |
||
|
9. |
Aggregate Amount Beneficially Owned by Each Reporting Person |
0 |
||
|
10. |
Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares |
o |
||
|
11. |
Percent of Class Represented by Amount in Row (9) |
0 |
||
|
12. |
Type of Reporting Person |
CO |
||
|
|
-5- |
|
CUSIP No. 06850R 10 8 |
Page 6 of 7 Pages |
Amendment No. 2 to Schedule 13G (Final Amendment)
Reference is hereby made to the statement on Schedule 13G originally filed with the Securities and Exchange Commission on February 8, 2005 and Amendment No. 1 thereto filed on February 9, 2006 (as so amended, the “Schedule 13G”). Terms defined in the Schedule 13G are used herein as so defined.
The following Items of the Schedule 13G are hereby amended and restated as follows:
|
ITEM 2(a) - |
NAME OF PERSON FILING: |
Item 2(a) is hereby amended to reflect that Janssen Pharmaceutica Products, L.P. (“JPP”) was dissolved on December 31, 2007 and its successor in interest is Ortho-McNeil-Janssen Pharmaceuticals, Inc. ("OMJP"), which is also a wholly-owned subsidiary of J&J, and is substituted for JPP herein as a Reporting Person.
|
ITEM 4 - |
OWNERSHIP: |
Item 4 is hereby amended and restated to read in its entirety as follows:
(a) Amount Beneficially Owned:
J&J: 0 shares of Common Stock
JJDC: 0 shares of Common Stock
OMJP: 0 shares of Common Stock
JJCC: 0 shares of Common Stock
(b) Percent of Class:
J&J: 0
JJDC: 0
OMJP: 0
JJCC: 0
(c) Number of shares as to which such persons have:
|
|
(i) sole power to vote or to direct the vote: 0 |
|
|
(ii) shared power to vote or to direct the vote: 0 |
(iii) sole power to dispose or to direct the disposition of: 0
(iv) shared power to dispose or to direct the disposition of: 0
|
ITEM 5 - |
OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS: |
If this statement is being filed to report the fact that as of the date hereof the reporting persons have ceased to be the beneficial owners of more than five percent of the Common Stock, check the following x.
|
|
-6- |
|
CUSIP No. 06850R 10 8 |
Page 7 of 7 Pages |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: February 14, 2009
|
|
JOHNSON & JOHNSON
|
|
|
|
By: |
/s/ Douglas Chia |
|
|
|
Name: Douglas Chia Title: Assistant Secretary
|
|
|
JOHNSON & JOHNSON DEVELOPMENT CORPORATION
|
|
|
|
By: |
/s/ Jayne Zall |
|
|
|
Name: Jayne Zall Title: Secretary |
|
|
ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC.
|
|
|
|
By: |
Michael C. Chester |
|
|
|
Name: Michael C. Chester Title: Secretary
|
|
|
JOHNSON & JOHNSON CONSUMER COMPANIES, INC.
|
|
|
|
By: |
Clayton H. Paterson |
|
|
|
Name: Clayton H. Paterson Title: Secretary
|
|
|
-7- |